SCHEMBL224556

SCHEMBL224556

CCN(CC)c1ccc(NC=O)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.59
ALDH3A1 P30838 1/20 0.59
ALDH1A3 P47895 1/20 0.59
MAPT P10636 7/20 0.53
RAB9A P51151 4/20 0.51
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
NOX1 Q9Y5S8 3/20 0.51
NPC1 O15118 3/20 0.51
GAA P10253 3/20 0.49
MCL1 Q07820 2/20 0.49
POLB P06746 1/20 0.49
MAPK1 P28482 4/20 0.47
TSHR P16473 3/20 0.47
GFER P55789 2/20 0.47
PSMD14 O00487 1/20 0.47
CYP3A4 P08684 1/20 0.47
RECQL P46063 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8762630 0.81 ALDH1A1 (0.55) ALDH1A1ALDH3A1ALDH1A3MAPTRAB9A
SCHEMBL11532092 0.80 MAPT (0.50) ALDH1A1ALDH3A1ALDH1A3MAPTRAB9A
SCHEMBL11332567 0.78 ALDH1A1 (0.49) ALDH1A1ALDH3A1ALDH1A3MAPTRAB9A
SCHEMBL10134048 0.77 ALDH1A1 (0.42) ALDH1A1ALDH3A1ALDH1A3MAPTRAB9A
SCHEMBL222553 0.77 LMNA (0.55) ALDH1A1MAPTRAB9AMEN1KMT2A
SCHEMBL7664793 0.76 ADRA2A (0.58) ALDH1A1ALDH3A1ALDH1A3MAPTRAB9A
SCHEMBL469386 0.75 ALDH1A1 (0.72) ALDH1A1MAPTRAB9AMEN1KMT2A
SCHEMBL1735497 0.75 ALDH1A1 (0.74) ALDH1A1ALDH3A1ALDH1A3MAPTRAB9A
SCHEMBL6141824 0.74 MAPT (0.55) ALDH1A1ALDH3A1ALDH1A3MAPTRAB9A
SCHEMBL5733313 0.74 ALDH1A1 (1.00) ALDH1A1ALDH3A1ALDH1A3MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3705481-A1 HETEROARYL AMIDE COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITIONS THEREOF, AND APPLICATIONS THEREOF Rui Jin Hospital Affiliated To Shanghai Jiao Tong University School of Medicine (CN) 2020-09-09 EP disclosed
WO-2019196111-A1 ANTI-TUMOR MULTIDRUG RESISTANCE OF HETEROARYL AMIDE COMPOUND, USE IN TREATMENT OF CANCERS AND PROTEIN-DRUG MOLECULAR COMPLEX 上海交通大学医学院附属瑞金医院 2019-10-17 WO disclosed
US-8637220-B2 Actinic ray-sensitive or radiation-sensitive resin composition, and resist film and pattern forming method using the composition FUJIFILM CORPORATION (JP) 2014-01-28 US disclosed
US-20120003583-A1 ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, AND RESIST FILM AND PATTERN FORMING METHOD USING THE COMPOSITION FUJIFILM CORPORATION (JP) 2012-01-05 US disclosed
US-20110039802-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2011-02-17 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110039802-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R ALDH1A1 4517/4885ALDH3A1 4340/4885ALDH1A3 4144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.